Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Related Posts
Here’s why inflation may look like it’s easing but is still a huge problem
By nearly every barometer, inflation is still well above where most Americans, and in fact some Fed officials, feel comfortable.
JPMorgan raises its year-end S&P 500 target, but sees little upside left
Head of global markets strategy Dubravko Lakos-Bujas’ updated year-end S&P 500 price target suggests just a 1% increase.
Wall Street analysts say Elon Musk is the clear auto tariff winner: ‘Tesla wins, Detroit bleeds’
Several Wall Street analysts see Tesla as benefiting from Trump’s plan for levies on cars.